ADAPY:OTCMKTS
Adaptimmune Therapeutics PLC - ADR
$0.034
0.00%
(0.00) 1D
Jun 8, 1:01:28 PM GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ADAPY...
Open
$0.03
High
$0.03
Low
$0.02
Mkt. cap
10.15M
Avg. vol.
439.86K
Volume
561.96K
52-wk high
$0.36
52-wk low
$0.00
EPS
-$0.66
Beta
1.75
Shares outstanding
265.05M
No. of employees
506
Open
$0.03
High
$0.03
Low
$0.02
Mkt. cap
10.15M
Avg. vol.
439.86K
Volume
561.96K
52-wk high
$0.36
52-wk low
$0.00
EPS
-$0.66
Beta
1.75
Shares outstanding
265.05M
No. of employees
506
News stories
From sources across the web
MJBizDaily
·
11 minutes ago
Trulieve to become first US cannabis company listed on NYSE
Business Wire
·
21 minutes ago
AppLovin to Participate in the 54th Nasdaq & Jefferies Investor Conference
Simply Wall Street
·
4 minutes ago
3 Stocks That May Be Priced Below Their Estimated Value In June 2026
Profile
Adaptimmune is a biopharmaceutical company that develops T cell therapies against cancer. The company was founded in 2008 in the UK with links to both Oxford University and the University of Pennsylvania. It has headquarters in Philadelphia and Milton Park.
In August 2024, the US Food and Drug Administration granted accelerated approval to Adaptimmune's Tecelra, a therapy against a rare form of cancer. Tecelra is the first T cell therapy to be approved for use against a solid tumor. In January 2025, the FDA granted breakthrough therapy designation to Adaptimmune's Letetresgene Autoleucel for Treatment of Myxoid/Round Cell Liposarcoma.
In July 2025, Adaptimmune announced their entry into a Definitive Agreement for Sale of Tecelra, lete-cel, and the pre-clinical uza-cel to US WorldMeds for $55M. Wikipedia
About Adaptimmune Therapeutics PLC - ADR
AI content may include mistakes. Learn more